Focused on genetic medicines for hearing loss, the company develops adeno-associated virus (AAV) gene therapies designed to restore or improve auditory function in patients with inherited inner-ear disorders. Its pipeline targets specific genetic mutations that lead to congenital or progressive hear...
2 members of Congress have disclosed 6 trades in Akou (AKOU), a Healthcare company. The buy/sell breakdown shows 5 purchases versus 1 sale, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2018-12-10 | JAMES B. RENACCI | buy | $1K – $15K |
| 2018-12-10 | JAMES B. RENACCI | sell | $1K – $15K |
| 2018-12-10 | JAMES B. RENACCI | buy | $15K – $50K |
| 2018-11-30 | MICHAEL T. MCCAUL | buy | $1K – $15K |
| 2017-09-14 | JAMES B. RENACCI | buy | $15K – $50K |
| 2015-02-19 | JAMES B. RENACCI | buy | $1K – $15K |